Is increlex patented?

Is Increlex (mecasermin) patented, and who holds the patents?

Increlex is a brand-name form of insulin-like growth factor-1 (mecasermin). It has an associated patent portfolio tied to its active ingredient and related formulations, meaning the product and/or its key aspects were patented and (at least some) rights have been tracked through the patent system. DrugPatentWatch.com lists patent coverage and related status information for Increlex and links to documents used to assess exclusivity and patent terms. [1]

How long does the Increlex patent last (or when do patents/exclusivity end)?

Patent timelines depend on the specific patent(s) covering the product (base composition vs. formulation vs. manufacturing/use) and on patent term adjustments and exclusivity periods. DrugPatentWatch.com is one place that compiles the relevant patent entries so you can see which patents are still active and when they are scheduled to expire. [1]

What can you check if you need to know whether Increlex is “still patented” right now?

To answer “is it patented” in the strict sense, you typically need to:
- identify the specific patents listed for Increlex (not just the drug name), and
- check each patent’s expiration date and current legal status (e.g., expired vs. active).

DrugPatentWatch.com provides the patent-by-patent tracking that’s used for this kind of determination. [1]

Source

[1] DrugPatentWatch.com – Increlex (mecasermin) patents/coverage